Point: Are we prepared for the future doctor visit?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

9 citing papers in PubMed.

1. Network Approaches for Precision Oncology.Advances in experimental medicine and biology · 2022
   Article
2. Patient Similarity Networks for Precision Medicine.Journal of molecular biology · 2018
   Review
3. Integrating translational bioinformatics into the medical curriculum.International journal of medical education · 2014
   Article
4. Managing Expectational Language: Translational genetic professionals consider the clinical potential of next-generation sequencing technologies.New genetics and society · 2014
   Article
5. Similarity network fusion for aggregating data types on a genomic scale.Nature methods · 2014
   Article
6. Pathway analyses and understanding disease associations.Current genetic medicine reports · 2013
   Article
7. Perspectives on systems biology applications in diabetic kidney disease.Journal of cardiovascular translational research · 2012
   Review
8. Next generation sequencing in clinical medicine: Challenges and lessons for pathology and biomedical informatics.Journal of pathology informatics · 2012
   Article
9. Protein-intrinsic and signaling network-based sources of resistance to EGFR- and ErbB family-targeted therapies in head and neck cancer.Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy · 2011
   Review

Corrections and comments

• Commented on by
  Counterpoint: Do not opine before it's time.2011
• Comment on
  Biomedical technology and the clinic of the future.2011

Authors and funding

2 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as